About Pluristem Therapeutics (NASDAQ:PSTI)
Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops PLacental eXpanded (PLX) cell therapy products, including PLX-PAD cells, which is Phase III clinical trial for the treatment of critical limb ischemia (CLI) in patients ineligible for revascularization, recovery after surgery for femoral neck fracture, and acute radiation syndrome (ARS), as well as peripheral and cardiovascular, and orthopedic diseases. It also develops PLX-R18 cells that is in Phase I clinical trial for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various in-vivo studies for the evaluation of PLX-R18 for the treatment of ARS. The company has collaborative research agreement with the Berlin-Brandenburg Center for Regenerative Therapies; and a license and commercialization agreement for conducting clinical trials and commercialization of its PLX-PAD product in South Korea related to the treatment CLI and intermediate claudication. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PSTI
CUSIPN/A
Phone972-74-710-8607
Debt
Debt-to-Equity RatioN/A
Current Ratio6.40%
Quick Ratio6.40%
Price-To-Earnings
Trailing P/E Ratio-3.80
Forward P/E Ratio-3.57
P/E GrowthN/A
Sales & Book Value
Annual Sales$2.85 million
Price / Sales47.27
Cash FlowN/A
Price / CashN/A
Book Value$0.31 per share
Price / Book3.92
Profitability
EPS (Most Recent Fiscal Year)($0.32)
Net Income$-27,810,000.00
Net MarginsN/A
Return on Equity-95.87%
Return on Assets-77.80%
Miscellaneous
Employees183
Outstanding Shares110,870,000
Pluristem Therapeutics (NASDAQ:PSTI) Frequently Asked Questions
What is Pluristem Therapeutics' stock symbol?
Pluristem Therapeutics trades on the NASDAQ under the ticker symbol "PSTI."
How were Pluristem Therapeutics' earnings last quarter?
Pluristem Therapeutics Inc. (NASDAQ:PSTI) announced its earnings results on Tuesday, November, 14th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.08). View Pluristem Therapeutics' Earnings History.
What price target have analysts set for PSTI?
4 Wall Street analysts have issued 1 year price targets for Pluristem Therapeutics' shares. Their forecasts range from $3.00 to $5.00. On average, they expect Pluristem Therapeutics' share price to reach $4.00 in the next twelve months. View Analyst Ratings for Pluristem Therapeutics.
What are Wall Street analysts saying about Pluristem Therapeutics stock?
Here are some recent quotes from research analysts about Pluristem Therapeutics stock:
- 1. Maxim Group analysts commented, "Pluristem announced a joint project with Indiana University to evaluate PLX- R18 cells in Acute Radiation Syndrome (ARS). The study will be supported with $2.5M in grant funding, and data from the first year of the study will be used to further support a BLA filing." (4/23/2018)
- 2. According to Zacks Investment Research, "PLURISTEM THERAPEUTICS INC. is a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products, stored ready-to-use, that are derived from the human placenta, a non-controversial source, and not from embryonic stem cells. " (3/27/2018)
Who are some of Pluristem Therapeutics' key competitors?
Some companies that are related to Pluristem Therapeutics include BioCryst Pharmaceuticals (BCRX), PDL Biopharma (PDLI), Solid Biosciences (SLDB), Vericel (VCEL), Nightstar Therapeutics (NITE), Agenus (AGEN), Cellular Biomedicine Gr (CBMG), Idera Pharmaceuticals (IDRA), Adverum Biotechnologies (ADVM), NantKwest (NK), Allena Pharmaceuticals (ALNA), Osiris Therapeutics (OSIR), Fennec Pharmaceuticals (FENC), NanoString Technologies (NSTG) and Arsanis (ASNS).
Who are Pluristem Therapeutics' key executives?
Pluristem Therapeutics' management team includes the folowing people:
- Mr. Zami Aberman, Chairman & Co-CEO (Age 64)
- Mr. Yaky Yanay, Pres, Co-CEO & Director (Age 47)
- Mr. Erez Egozi, CFO, Treasurer & Sec. (Age 44)
- Mr. Boaz Leshem, VP Operations & Manufacturing (Age 58)
- Efrat Kaduri, Head of Investor & PR
Has Pluristem Therapeutics been receiving favorable news coverage?
News stories about PSTI stock have trended somewhat positive on Monday, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Pluristem Therapeutics earned a media sentiment score of 0.22 on Accern's scale. They also assigned news coverage about the biotechnology company an impact score of 45.94 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
How do I buy shares of Pluristem Therapeutics?
Shares of PSTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Pluristem Therapeutics' stock price today?
One share of PSTI stock can currently be purchased for approximately $1.2150.
How big of a company is Pluristem Therapeutics?
Pluristem Therapeutics has a market capitalization of $133.04 million and generates $2.85 million in revenue each year. The biotechnology company earns $-27,810,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis. Pluristem Therapeutics employs 183 workers across the globe.
How can I contact Pluristem Therapeutics?
Pluristem Therapeutics' mailing address is MATAM ADVANCED TECHNOLOGY PARK BUILDING NO. 5, HAIFA L3, 31905. The biotechnology company can be reached via phone at 972-74-710-8607 or via email at [email protected]
MarketBeat Community Rating for Pluristem Therapeutics (PSTI)
MarketBeat's community ratings are surveys of what our community members think about Pluristem Therapeutics and other stocks. Vote "Outperform" if you believe PSTI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PSTI will underperform the S&P 500 over the long term. You may vote once every thirty days.
Pluristem Therapeutics (NASDAQ:PSTI) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for Pluristem Therapeutics in the last 12 months. Their average twelve-month price target is $4.00, suggesting that the stock has a possible upside of 229.22%. The high price target for PSTI is $5.00 and the low price target for PSTI is $3.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $4.00 | $4.00 | $4.00 | $4.1250 |
| Price Target Upside: | 229.22% upside | 194.12% upside | 148.45% upside | 137.07% upside |
Pluristem Therapeutics (NASDAQ:PSTI) Consensus Price Target History
Pluristem Therapeutics (NASDAQ:PSTI) Analyst Ratings History
Show:
(Data available from 4/23/2016 forward)
Pluristem Therapeutics (NASDAQ:PSTI) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Pluristem Therapeutics (NASDAQ PSTI) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 7.20%
Institutional Ownership Percentage: 4.17%
Pluristem Therapeutics (NASDAQ PSTI) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/16/2018 | Mark Germain | Director | Sell | 45,873 | $1.48 | $67,892.04 | 525,584 |  |
| 3/14/2018 | Mark Germain | Director | Sell | 23,818 | $1.50 | $35,727.00 | 559,817 | |
| 2/22/2016 | Zami Aberman | CEO | Buy | 5,000 | $1.33 | $6,650.00 | 2,118,298 | |
| 2/18/2016 | Yaky Yanay | CFO | Buy | 5,000 | $1.20 | $6,000.00 | 1,451,616 | |
| 2/16/2016 | Yaky Yanay | CFO | Buy | 15,000 | $0.95 | $14,250.00 | 1,451,616 | |
| 2/15/2016 | Doron Shorrer | Director | Buy | 12,346 | $0.81 | $10,000.26 | | |
| 2/12/2016 | Yaky Yanay | CFO | Buy | 5,000 | $0.83 | $4,150.00 | 1,451,616 | |
| 2/11/2016 | Israel Ben-Yoram | Director | Buy | 10,000 | $0.79 | $7,900.00 | 216,056 | |
| 2/11/2016 | Zami Aberman | CEO | Buy | 31,000 | $0.80 | $24,800.00 | 2,118,298 | |
| 11/16/2015 | Yaky Yanay | CFO | Buy | 10,000 | $1.52 | $15,200.00 | 1,301,616 | |
| 11/16/2015 | Zami Aberman | CEO | Buy | 9,900 | $1.49 | $14,751.00 | 1,968,298 | |
| 9/21/2015 | Israel Ben-Yoram | Director | Sell | 30,000 | $2.10 | $63,000.00 | 206,056 | |
| 9/21/2015 | Yaky Yanay | CFO | Buy | 10,000 | $2.11 | $21,100.00 | 1,301,616 | |
| 9/21/2015 | Zami Aberman | CEO | Buy | 25,500 | $2.11 | $53,805.00 | 1,968,298 | |
| 9/16/2015 | Yaky Yanay | CFO | Buy | 10,000 | $2.12 | $21,200.00 | 1,301,616 | |
| 9/15/2015 | Zami Aberman | CEO | Buy | 25,000 | $2.11 | $52,750.00 | 1,968,298 | |
| 11/11/2014 | Yaky Yanay | COO | Buy | 11,000 | $2.62 | $28,820.00 | | |
| 11/11/2014 | Zami Aberman | CEO | Buy | 13,000 | $2.64 | $34,320.00 | | |
| 9/22/2014 | Yaky Yanay | COO | Buy | 11,000 | $2.95 | $32,450.00 | | |
| 9/22/2014 | Zami Aberman | CEO | Buy | 5,000 | $2.92 | $14,600.00 | | |
| 9/21/2014 | Zami Aberman | CEO | Buy | 5,000 | $2.96 | $14,800.00 | | |
| 9/17/2014 | Israel Ben-Yoram | Director | Buy | 5,000 | $2.82 | $14,100.00 | | |
| 9/16/2014 | Boaz Gur-Lavie | CFO | Buy | 3,478 | $2.84 | $9,877.52 | | |
| 9/16/2014 | Yaky Yanay | COO | Buy | 10,000 | $2.85 | $28,500.00 | | |
| 9/16/2014 | Zami Aberman | CEO | Buy | 15,000 | $2.80 | $42,000.00 | | |
| 6/18/2014 | Mark Germain | Director | Sell | 43,215 | $3.12 | $134,830.80 | | |
| 1/17/2014 | Israel Ben-Yoram | Director | Sell | 35,625 | $4.51 | $160,668.75 | 314,806 | |
| 1/13/2014 | Israel Ben-Yoram | Director | Sell | 26,453 | $4.29 | $113,483.37 | 350,431 | |
| 1/13/2014 | Yaky Yanay | CFO | Sell | 69,850 | $4.29 | $299,656.50 | 1,069,616 | |
| 1/9/2014 | Yaky Yanay | CFO | Sell | 30,150 | $4.25 | $128,137.50 | 1,139,466 | |
| 1/8/2014 | Israel Ben-Yoram | Director | Sell | 44,797 | $4.12 | $184,563.64 | 376,884 | |
| 11/11/2013 | Nachum Rosman | Director | Sell | 67,244 | $3.27 | $219,887.88 | | |
| 9/12/2013 | Israel Ben-Yoram | Director | Sell | 52,000 | $3.07 | $159,640.00 | 371,681 | |
| 5/20/2013 | Israel Ben-Yoram | Director | Sell | 45,429 | $3.03 | $137,649.87 | | |
(Data available from 1/1/2013 forward)
Pluristem Therapeutics (NASDAQ PSTI) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Maxim Group Analysts Give Pluristem Therapeutics (PSTI) a $3.00 Price Target
www.americanbankingnews.com - April 23 at 11:28 AM |
| Pluristem Therapeutics Inc. (PSTI) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 23 at 9:30 AM |
 | Pluristem and Indiana University to Initiate Joint Project Evaluating PLX-R18 in Acute Radiation Syndrome, Targeting Bridging Data for Pivotal Study
finance.yahoo.com - April 23 at 8:16 AM |
| Pluristem Therapeutics (PSTI) Rating Reiterated by MED
www.americanbankingnews.com - April 23 at 7:40 AM |
| -$0.09 EPS Expected for Pluristem Therapeutics Inc. (PSTI) This Quarter
www.americanbankingnews.com - April 17 at 7:08 PM |
| Acorda Therapeutics (ACOR) & Pluristem Therapeutics (PSTI) Financial Contrast
www.americanbankingnews.com - April 13 at 11:51 AM |
| Pluristem Therapeutics (PSTI) Upgraded by ValuEngine to Sell
www.americanbankingnews.com - April 8 at 11:17 AM |
| Roger Jeffs, Former Co-CEO of United Therapeutics, Joins Pluristem's Strategic Advisory Board
finance.yahoo.com - April 6 at 5:41 PM |
| Pluristem Therapeutics (PSTI) PT Set at $3.00 by Maxim Group
www.americanbankingnews.com - April 2 at 6:58 PM |
| CytRx (CYTR) vs. Pluristem Therapeutics (PSTI) Critical Contrast
www.americanbankingnews.com - April 1 at 5:38 AM |
| Analysts Anticipate Pluristem Therapeutics Inc. (PSTI) to Post -$0.08 EPS
www.americanbankingnews.com - March 31 at 7:14 PM |
| Pluristem Therapeutics (PSTI) Receives Buy Rating from HC Wainwright
www.americanbankingnews.com - March 31 at 5:28 PM |
| HC Wainwright Analysts Give Pluristem Therapeutics (PSTI) a $4.00 Price Target
www.americanbankingnews.com - March 28 at 2:06 PM |
| Pluristem Therapeutics (PSTI) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - March 27 at 10:01 AM |
| Pluristem Therapeutics (PSTI) Upgraded to "Buy" by Zacks Investment Research
www.americanbankingnews.com - March 24 at 2:26 PM |
| Pluristem Therapeutics (PSTI) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - March 20 at 8:13 AM |
| Pluristem Therapeutics Inc. (PSTI) Director Sells $67,892.04 in Stock
www.americanbankingnews.com - March 19 at 8:28 PM |
| Pluristem Therapeutics Inc. (PSTI) Director Mark Germain Sells 23,818 Shares
www.americanbankingnews.com - March 15 at 8:28 PM |
| Pluristem Therapeutics (PSTI) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - March 15 at 10:02 AM |
| Pluristem Therapeutics Inc. (PSTI) Expected to Announce Earnings of -$0.08 Per Share
www.americanbankingnews.com - March 14 at 5:24 PM |
 | Pluristem (PSTI) Says PLX-R18 Improves Hematopoietic Transplantation as Reported in Scientific Journal Frontiers in ... - StreetInsider.com
www.streetinsider.com - February 27 at 8:19 AM |
| Pluristem’s PLX-R18 Improves Hematopoietic Transplantation as Reported in Scientific Journal Frontiers in Medicine
finance.yahoo.com - February 27 at 8:19 AM |
| Financial Survey: Regulus Therapeutics (RGLS) versus Pluristem Therapeutics (PSTI)
www.americanbankingnews.com - February 27 at 5:14 AM |
| Pluristem Therapeutics (PSTI) Given a $3.00 Price Target at Maxim Group
www.americanbankingnews.com - February 25 at 1:50 PM |
| What You Must Know About Pluristem Therapeutics Inc’s (NASDAQ:PSTI) Major Investors
finance.yahoo.com - February 16 at 8:18 AM |
| Pluristem Issues Letter to Shareholders
finance.yahoo.com - February 7 at 9:41 AM |
| Pluristem Therapeutics (PSTI) Set to Announce Earnings on Monday
www.americanbankingnews.com - February 5 at 4:00 AM |
| N.Korea threats spur U.S. search for new radiation therapies
finance.yahoo.com - January 31 at 3:43 PM |
| Critical Comparison: GenVec (GNVC) and Pluristem Therapeutics (PSTI)
www.americanbankingnews.com - January 11 at 5:36 AM |
| FDA Clears Pluristem’s Expanded Access Program to Initiate Treatments of Critical Limb Ischemia Outside of Ongoing Phase III Study
finance.yahoo.com - January 9 at 10:13 AM |
| Pluristem Therapeutics (PSTI) versus ACADIA Pharmaceuticals (ACAD) Financial Contrast
www.americanbankingnews.com - January 8 at 3:30 AM |
| Brokerages Expect Pluristem Therapeutics Inc. (PSTI) to Post -$0.09 EPS
www.americanbankingnews.com - January 5 at 11:06 PM |
| Does Pluristem Therapeutics Inc’s (NASDAQ:PSTI) Past Performance Indicate A Weaker Future?
finance.yahoo.com - December 25 at 6:08 PM |
| Pluristem Therapeutics (PSTI) Downgraded by ValuEngine
www.americanbankingnews.com - December 20 at 10:10 PM |
| -$0.09 Earnings Per Share Expected for Pluristem Therapeutics, Inc. (PSTI) This Quarter
www.americanbankingnews.com - December 20 at 1:18 PM |
| Pluristem Therapeutics, Inc. (PSTI) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - December 20 at 1:28 AM |
| Wired News – VistaGen Receives US Patent on Methods for Producing Blood Cells, Platelets, and Bone Marrow Stem Cells
finance.yahoo.com - December 12 at 10:46 AM |
| Pluristem Therapeutics (PSTI) & Protagonist Therapeutics (PTGX) Head to Head Comparison
www.americanbankingnews.com - December 11 at 1:36 PM |
| Pluristem to Present Data on PLX-R18 in Treatment of Acute Radiation Syndrome at American Society of Hematology’s Annual Meeting
finance.yahoo.com - December 7 at 10:42 AM |
 | Peer-Reviewed Article Published on Pluristem's PLX-PAD Cells' Mechanism of Action to Restore Blood Flow in ... - GlobeNewswire (press release)
globenewswire.com - November 30 at 4:34 PM |
| Peer-Reviewed Article Published on Pluristem’s PLX-PAD Cells’ Mechanism of Action to Restore Blood Flow in Ischemic Tissue
finance.yahoo.com - November 29 at 10:24 AM |
| Comparing Pluristem Therapeutics (PSTI) & The Competition
www.americanbankingnews.com - November 25 at 5:10 PM |
| Pluristem Therapeutics (PSTI) Granted US Patent for Skeletal Muscle Regeneration - StreetInsider.com
www.streetinsider.com - November 23 at 5:46 PM |
| Pluristem Therapeutics, Inc. (PSTI) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - November 22 at 10:04 PM |
| Pluristem Reports First Quarter Fiscal 2018 Corporate and Financial Highlights
finance.yahoo.com - November 15 at 7:40 AM |
| Pluristem Therapeutics, Inc. (PSTI) Announces Earnings Results
www.americanbankingnews.com - November 14 at 7:16 AM |
| Is It Time To Buy Pluristem Therapeutics Inc (PSTI)?
finance.yahoo.com - November 14 at 7:01 AM |
| Pluristem Therapeutics, Inc. (PSTI) Short Interest Update
www.americanbankingnews.com - November 13 at 2:32 AM |
| Pluristem reports 1Q loss
finance.yahoo.com - November 9 at 11:59 AM |
| Pluristem Enters into Agreement with Tel Aviv Sourasky Medical Center to Conduct Phase I/II Trial in Steroid-Refractory Chronic GvHD
finance.yahoo.com - November 7 at 9:06 AM |
Pluristem Therapeutics (NASDAQ:PSTI) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Pluristem Therapeutics (NASDAQ:PSTI) Income Statement, Balance Sheet and Cash Flow Statement
Pluristem Therapeutics (NASDAQ PSTI) Stock Chart for Monday, April, 23, 2018
Loading chart…
